Imugene (ASX:IMU) will raise AU$46 million via the issue of notes and warrants to investor CVI Investments, according to a Monday filing with the Australian bourse.
The offer comprises AU$20 million in senior unsecured zero-coupon convertible notes maturing in five years and AU$26 million worth of five-year unlisted warrants exercisable at AU$0.0494, the filing said.
If the investor decides to convert the bonds into shares, its conversion value will be 25% above the immuno-oncology firm's closing price on Dec. 20, per the filing.
Proceeds will be used to advance the company's azer-cel, onCARlytics, and Vaxinia trials, as per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.